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Background: Functional dyspepsia (FD) is a common health problem currently without any optimal treatments.
Acupuncture has been traditionally sought as a treatment for FD. The aim of this study is to investigate whether
acupuncture treatment helps improve symptoms of FD.
Methods/design: A two-center, randomized, waitlist-controlled trial will be carried out to evaluate whether acupuncture
treatment improves FD symptoms. Seventy six participants aged 18 to 75 years with FD as diagnosed by Rome III criteria
will be recruited from August 2013 to January 2014 at two Korean Medicine hospitals. They will be randomly allocated
either into eight sessions of partially individualized acupuncture treatment over 4 weeks or a waitlist group. The
acupuncture group will then be followed-up for 3 weeks with six telephone visits and a final visit will be paid at 8 weeks.
The waitlist group will receive the identical acupuncture treatment after a 4-week waiting period. The primary outcome is
the proportion of responders with adequate symptom relief and the secondary outcomes include Nepean dyspepsia
index, EQ-5D, FD-related quality of life, Beck’s depression inventory, state-trait anxiety inventory questionnaire, and level of
ghrelin hormone. The protocol was approved by the participating centers’ Institutional Review Boards.
Discussion: Results of this trial will help clarify not only whether the acupuncture treatment is beneficial for symptom
improvement in FD patients but also to elucidate the related mechanisms of how acupuncture might work.
Trial registration: ClinicalTrials.gov Identifier: NCT01921504.
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Functional dyspepsia (FD) is a functional gastrointestinal
disorder without any structural lesion [1]. It is reported that
the prevalence of FD ranges from 8% to 23% in Asia [2],
and in particular, FD is claimed to affect 25% of the South
Korean population [3]. Though FD is not a life-threatening
disease, FD patients suffer from a poor quality of life (QoL),
which is regarded as an economic burden on society [4].
Although various treatments for FD, such as proton pump
inhibitors, prokinetic agents, tricyclic antidepressants,
and antinociceptive agents are available [5-9], many* Correspondence: erc633@khu.ac.kr
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unless otherwise stated.FD patients turn to other complementary and alterna-
tive therapies largely due to a lack of satisfactory relief
by these treatments [10].
Acupuncture treatment is one of the most sought-after
therapeutic modalities in complementary and alternative
medicine. It has been frequently used to treat symptoms
of FD [11] largely based on the following rationales:
firstly, acupuncture is well known to relieve pain in vari-
ous conditions [12] and may help reduce epigastric pain
or burning sensation [4]; secondly, previous studies have
shown that manual acupuncture and electro-acupuncture
modulates gastric/duodenal motility through the activation
of sympathetic efferent nerve fibers or vagal nerve fibers
[13]; finally, since patients with FD have been reported to
have higher levels of psychological distress or depression
than healthy subjects [14,15], the anxiolytic or antidepressant. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,


























Figure 1 Flow of the study.
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ening of FD symptoms [16-18].
However, previous studies have reported inconsistent
findings of the clinical benefit of acupuncture treatment
for FD [4,19]. Nevertheless, these studies have been criti-
cized for adopting relatively sub-optimal acupuncture
treatment, i.e., three times a week for 2 weeks [19,20], or
testing a less generalizable treatment regimen, i.e., daily
acupuncture treatment for 4 weeks [4]. According to a
systematic review by Zhu [21], the acupuncture treat-
ment for FD lacks high-quality evidence. Hence, it was
addressed that randomized clinical trials corresponding
with the CONSORT statement and STandards for Reporting
Interventions in Clinical Trials of Acupuncture (STRICTA)
recommendations have to be implemented to evaluate the
efficacy of acupuncture for FD. In addition, considering the
questions which have been raised so far on the adequacy of
various sham acupuncture controls [22,23], care should be
taken before simply adopting any available sham devices or
procedures in the early phase.
Given that FD is now regarded as a complex disorder
of which the pathophysiological mechanisms are incon-
clusive [24], various factors are likely to come into play.
Among them, ghrelin, an orexigenic peptide, has been
shown to play an important role in gastric motility, food
intake, and potential gastroprotection against acute gas-
tric mucosal injury [25,26]. However, it is yet to be stud-
ied whether ghrelin is associated with the mechanisms
of acupuncture treatment in patients with FD [27,28].
Taken together, we felt the need to properly test
whether acupuncture treatment would help symptom
improvement in FD patients and, subsequently, the re-
lated mechanism. Therefore, we propose a two-center,
randomized, waitlist-controlled trial investigating the ef-
fectiveness of acupuncture for symptom improvement in
patients with FD and to assess whether the change in
ghrelin secretion is associated with acupuncture treatment.
Methods/design
Objectives
The aims of this study are to: i) assess the effect of acu-
puncture treatment on patients with FD in comparison
with waitlist group with respect to adequate symptom
relief and ii) to elucidate whether ghrelin level is associ-
ated with clinical effect of acupuncture.
Hypothesis
We hypothesize that eight sessions of acupuncture treat-
ment over 4 weeks will improve symptoms of FD.
Design
A two-center, randomized, waitlist-controlled trial will be
conducted at the Kyung Hee University Korean Medicine
Hospital and Kyung Hee University Hospital at Gangdongin Seoul, Korea from August 2013 to January 2014. The
flow of the entire trial is shown in Figure 1.
Inclusion and exclusion criteria
Inclusion criteria
Participants who meet the following criteria will be included:
i) Individuals between the ages of 18 and 75 years, able
to read and write Korean language
ii) Individuals who meet the Rome III FD criteria
iii) Individuals who check more than four points on the
visual analogue scale (VAS; 0, no symptom disturbance
at all; 10, very severe) for dyspeptic symptoms
iv) Individuals who have normal
esophagogastroduodenoscopy results within a year
and have been diagnosed with FD by a specialist
consultation
v) Individuals who receive no other treatments during
the study
vi) Individuals who voluntarily agree with a study
protocol and sign a written informed consent
Exclusion criteria
Participants who report any of the following will be
excluded:
i) Individuals who have peptic ulcer or
gastroesophageal reflux disease confirmed by
esophagogastroduodenoscopy
ii) Individuals who have obvious signs of irritable bowel
syndrome
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black or tar stool, or dysphagia)
iv) Individuals who have serious structural disease
(disease of heart, lung, liver or kidney) or mental
illness
v) Individuals who have had surgery related with the
gastrointestinal tract, except for appendectomy more
than six months ago
vi) Individuals who are pregnant or breastfeeding
vii) Individuals who are taking drugs which might affect
the gastrointestinal tract; a minimum wash-out
period of two weeks is required before participating
in the trial
viii) Individuals who are HIV-positive
ix) Individuals who have a problem of malabsorption or
maldigestion
x) Individuals who have difficulties in attending the
trial (e.g., paralysis, serious mental illness, dementia,
drug addiction, time constraint, severe disorder in
vision or hearing, illiteracy)
xi) Individuals unwilling to sign the informed consent
xii)Individuals with other diseases that could interfere
with acupuncture treatment, e.g., clotting disorders
or leukopenia, pace-maker, epilepsy, or anticoagulant
therapy
Recruitment
Patients who have participated in our previous studies
will be contacted to ask if they are interested. Advertise-
ments will be put on notice boards and homepages of
the hospitals, advertising boards on the subway trains,
and local newspapers. Obtaining consent will be carried
out by the investigators with the principle of informed
consent, which consists of information, decisional cap-
acity, and voluntarism. The participants will sign two
written informed consent forms, general consent form
and additional consent provisions for collection and use
of their human biologic material, and go through the
screening test. The model consent form and other re-
lated documentation given to participants can be pro-
vided upon request.
Randomization
After signing an informed consent and undergoing the
screening test, the participants in each hospital will be ran-
domly assigned to one of the two groups using block
randomization. Random numbers will be generated using
the PROC PLAN of SAS 9.2 (SAS Institute Inc., Cary, NC,
USA) by an independent statistician and sent to the Acu-
puncture and Meridian Science Research Center (AMSRC)
at Kyung Hee University where the each randomization
number will be put in a sequentially numbered opaque en-
velope and remain sealed by an administrative staff who is
otherwise not involved in the study.Once a participant passes the screening test, the inves-
tigator will call the AMSRC staff who is responsible for
this randomization process to give her the hospital
name, and the initial and screening number of the par-
ticipant. The AMSRC staff will then immediately fax a
document containing a unique random number and par-
ticipant group allocation. This feedback document will
be kept in the trial master file.
Intervention
Acupuncture treatment
Detailed information on acupuncture treatment is sum-
marized based on the revised STRICTA recommendations
[29] in Table 1. The acupuncture treatment procedures
were designed to reflect the real clinical setting.
In this trial, partially-individualized manual acupunc-
ture treatments based on the traditional meridian theory
and consensus by the experts in acupuncture and FD,
will be given. The number of inserted needles per par-
ticipant per session ranges from 9 to 19. The acupunc-
ture points consist of basic points and optional points.
All participants will be given needling at nine fixed
points: Large Intestine 4, Stomach (ST) 36, Liver 3, and
Spleen 4 bilaterally, and Conception Vessel 12 unilat-
erally. The optional points include Gallbladder (GB) 21,
Small Intestine (SI) 14, Pericardium (PC) 6, Extra acu-
point of Head and Neck (EX-HN) 5, and ST 34. These
optional points will be selected according to the partici-
pant’s symptoms such as headache (EX-HN5), shoulder
or back pain (GB21, SI14), nausea and/or vomiting
(PC6), and heartburn or epigastric pain (ST34). Two
additional Ah-Shi points in the medial scapular region
will be allowed in case of shoulder or back pain.
The questions about symptoms related to optional
points will be asked to participants by the clinical re-
search coordinator to minimize the bias induced by con-
tact between doctor and participant.
A sterilized stainless steel needle (40 mm length and
0.25 mm diameter; Dongbang Acupuncture Inc., Bundang,
Sungnam, Korea) will be used. The depth of needle inser-
tion will be from 5 mm to 30 mm and needle manipula-
tion to achieve ‘de qi’ sensation will be performed. The
acupuncture needles will be retained for 15 min.
All acupuncture treatments will be provided by the
same Korean Medicine Doctor at each hospital, who will
have undergone 10 hours of training and simulation
to ensure that they are able to provide identical acu-
puncture treatment in accordance with a pre-defined
protocol.
Acupuncture group
The participants in the acupuncture group will receive
eight acupuncture sessions over 4 weeks. After the treat-
ment period, they will be followed-up for 3 weeks with
Table 1 Acupuncture treatment details based on the STRICTA 2010 checklist [29]
Item Detail
1. Acupuncture rationale 1a) Style of acupuncture
- Manual acupuncture based on traditional meridian theory.
1b) Reasoning for treatment provided, based on historical context, literature sources, and/or consensus methods,
with references where appropriate
- Partially-individualized manual acupuncture treatments based on the traditional meridian theory, clinical experience, and
consensus by the experts in acupuncture and FD.
1c) Extent to which treatment was varied
- Partially-individualized acupuncture treatment, i.e., fixed points plus optional points according to symptoms.
2. Details of needling 2a) Number of needle insertions per subject per session (mean and range where relevant)
- From 9 to 19.
2b) Names (or location if no standard name) of points used (uni/bilateral)
- Nine fixed points: LI4, ST36, LR3, and SP4 (bilateral) and CV12 (unilateral).
- Optional points according to individual symptoms: GB21, SI14, PC6, EX-HN5, and ST34 (bilateral).
2c) Depth of insertion, based on a specified unit of measurement, or on a particular tissue level
- From 5 to 30 mm.
2d) Response sought (e.g., de qi or muscle twitch response)
- ‘De qi’ sensation.
2e) Needle stimulation (e.g., manual, electrical)
- Manual stimulation: needle rotation with thumb and index fingers at 3 Hz.
2f) Needle retention time
- Fifteen minutes.
2g) Needle type (diameter, length, and manufacturer or material)
- A sterilized stainless steel needle (0.25 × 40 mm, Dongbang Acupuncture Inc., Bundang, Sungnam, Korea).
3. Treatment regimen 3a) Number of treatment sessions
- Eight treatment sessions in both acupuncture and waitlist groups.
3b) Frequency and duration of treatment sessions
- Twice weekly for 4 weeks, 15 minutes for each session.
4. Other components of
treatment
4a) Details of other interventions administered to the acupuncture group (e.g., moxibustion, cupping, herbs,
exercises, lifestyle advice)
- No other interventions during the study period allowed.
4b) Setting and context of treatment, including instructions to practitioners, and information and explanations
to patients
- University hospitals.
- Participants will be informed about acupuncture treatment in the study as follows: “In this study, acupoint for FD will be
used based on traditional Korean medicine textbook and FD-related reports.”
5. Practitioner background 5) Description of participating acupuncturists (qualification or professional affiliation, years in acupuncture
practice, other relevant experience)
- Korean Medicine Doctors who have a license and at least 3 years of experience in gastrointestinal disorders. They went
through 10 hours of training and simulation to ensure that they are able to provide identical acupuncture treatment in
accordance with a pre-defined protocol.
6. Control or comparator
interventions
6a) Rationale for the control or comparator in the context of the research question, with sources that justify this
choice
- A waitlist group will be adopted as a first step before we move on to a sham controlled trial.
6b) Precise description of the control or comparator. If sham acupuncture or any other type of acupuncture-like
control is used, provide details as for items 1 to 3 above.
- Participants in the waitlist will not receive acupuncture treatment after randomization for 4 weeks, during which period,
there will be six telephone visits. After this waiting period, they then will receive twice weekly acupuncture sessions for
4 weeks in the same manner as in the acupuncture group.
CV, Conception Vessel; EX-HN, Extra acupoint of Head and Neck; FD, functional dyspepsia; GB, Gallbladder; LI, Large Intestine; LR, Liver; PC, Pericardium; SI, Small
Intestine; SP, Spleen; ST, Stomach; STRICTA, STandards for Reporting Interventions in Clinical Trials of Acupuncture.
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they will pay a final visit at 8 weeks. No other interven-
tions during the study period will be allowed and a diary
will be collected.
Waitlist group
The participants in the waitlist group will not receive
acupuncture treatment after randomization for 4 weeks,
during which period there will be six telephone visits
once or twice a week. After this waiting period, they will
then receive twice weekly acupuncture sessions for
4 weeks in the same manner as in the acupuncture
group. No other interventions during the study period
will be allowed and a diary will be collected.
Outcome measures
A nurse in each center who is otherwise involved in the
study will give the participants a set of outcome mea-
sures to complete in addition to the primary outcome
measure; its schedule is summarized in Table 2.
Primary outcome
The primary outcome is the proportion of responders
(PR) [30], which is the proportion of subjects who an-
swer “yes” to more than half of adequate relief questions
in the treatment period. Participants are asked to answer
the following question at each visit during the treatment
period (twice weekly for 4 weeks), at each telephone visit
during the waiting period, and at the follow-up visit:
“After the last visit, have you had adequate relief of your
stomach pain or discomfort?” Responders are defined asTable 2 Study schedule for data collection
Measures Baseline 1-week 2-wee
Sociodemographic data ✔
Adequate relief† for the acupuncture group ✔ ✔ ✔
Adequate relief§ for the waitlist group ✔ ✔ ✔
Visual analogue scale for dyspepsia ✔
Nepean Dyspepsia Index – Korean ✔
Functional Dyspepsia-Related Quality of Life ✔
EuroQol-5 Dimensions ✔
Functional Dyspepsia-related costs ✔
Beck’s Depression Inventory ✔
The State-Trait Anxiety Inventory ✔
Blood collection for ghrelin analysis ✔
Adverse events investigation‡ ✔ ✔ ✔
Concomitant therapy evaluation ✔ ✔ ✔
± 1 day interval was allowed for each visit.
*8-week indicates 4 weeks after the 4-week acupuncture treatment.
†Adequate relief data will be collected by a telephone interview from 5 to 7 weeks
§Adequate relief data will be collected by a telephone interview from 1 to 4 weeks
‡Adverse event data for the waitlist group will be collected from 5 to 8 weeks.participants reporting adequate relief for at least 50% of
the study period, i.e., responding “Yes” more than four
times out of eight. The proportion of responders will be
compared between the acupuncture group and the wait-
list group.
Secondary outcomes
Nepean Dyspepsia Index – Korean version (NDI-K)
The Nepean Dyspepsia Index (NDI) [31,32] is a reliable
and valid measure of QoL in FD. The NDI originally con-
tains 42 items designed to measure symptoms and health-
related QoL in dyspepsia. We will use the Korean version
of NDI (NDI-K), as validated in 2004 by Lee et al. [33],
consisting of two sections about symptom-based ques-
tions and QoL. In this trial, symptom-based questions
such as period, severity, and degree of distress of 15 symp-
toms will be evaluated at baseline, 4 weeks, and 8 weeks.
EuroQol-5 Dimensions (EQ-5D) EuroQol-5 Dimensions
(EQ-5D) [34,35] is one of the standardized preference-
based instruments as a measure of health-related QoL. This
self-report questionnaire consists of an EQ-5D index and
an EQ-5D VAS. To assess the index-based values (utilities),
the three-level version of EQ-5D on five dimensions (mo-
bility, self-care, usual activities, pain/discomfort, and anx-
iety/depression) will be used. EQ-5D VAS records an
individual’s rating for his/her current health-related QoL
state on a standard vertical 20 cm VAS (similar to a therm-
ometer) where the endpoints are labelled as ‘best imagin-
able health state’ at the top and ‘worst imaginable health
state’ at the bottom, respectively. A validated Koreank 3-week 4-week 5-week 6-week 7-week 8-week*
✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔









✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔
✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔
for the acupuncture group.
for the waitlist group.
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This measurement will be carried out at baseline and after
4 and 8 weeks.
Costs FD-related costs will be assessed using medical re-
cords and a pre-defined questionnaire to collect direct
medical cost including clinic or hospital care and prescrip-
tion or over-the-counter drugs, and direct non-medical
costs including formal/informal care and transportation
costs. Time lost for doctor visits and absence from paid
work due to FD will be taken from patients’ self-reported
questionnaires. Direct medical costs used in this study,
such as acupuncture costs, will reflect the real world situ-
ation in Korea from a societal perspective. Additional re-
source consumption data from patients will be measured
at baseline and after 4 and 8 weeks.
Functional Dyspepsia-Related Quality of Life (FD-
QoL) questionnaire The FD-QoL questionnaire is com-
posed of four categories of diet (five items), daily activity
(four items), emotion (six items), and social functioning
(six items). Higher total sum scores of FD-QoL indicate
worse QoL. The questionnaire to be used in this study
was validated among Korean FD patients in the previous
study [37] and the measurement will be done at baseline,
4 weeks, and 8 weeks.
Beck’s Depression Inventory (BDI) The Beck’s Depres-
sion Inventory (BDI) [38] is one of the most widely used
instruments for measuring the severity of depression. This
is a self-report inventory and consists of 21 multiple-
choice questions. The participants will complete the BDI
at baseline, 4 weeks, and 8 weeks.
The State-Trait Anxiety Inventory (STAI) The State-
Trait Anxiety Inventory (STAI) [39] is a psychological inven-
tory to evaluate the degree of anxiety based on a 4-point
Likert scale and consists of 40 items on a self-report basis.
The STAI measures two types of anxiety – state of anxiety
(20 items; anxiety triggered by a specific event) and trait of
anxiety (20 items; anxiety derived from personal characteris-
tic). Higher scores are positively correlated with higher levels
of anxiety. This measurement will be completed at baseline,
4 weeks, and 8 weeks.
Ghrelin measurement (total ghrelin and deacylated
ghrelin) Ghrelin is mostly secreted by endocrine cells in
the oxyntic mucosa of the stomach [40,41] and is present
in the peripheral circulation as two subtypes: acylated and
unacylated [42]. Its physiologic functions include regulat-
ing food intake [43,44] and secretion of gastric acid [45],
accelerating gastric emptying [46], and stimulating gastric
motility [47,48]. In our study, approximately 6 mL of
whole blood, 3 mL each for total and unacylated ghrelin,will be collected on an empty stomach at baseline and at
4 weeks. The total and unacylated ghrelin assay will be
performed using the commercially available radio-
immunoassay and enzyme-linked immunosorbent assay
kits.
Sample size calculation
Sample size was determined based on our clinical ex-
perience and previous reports where the waitlist group
achieved approximately 28% of the PR in patients with
irritable bowel syndrome [49]; in our study, we expected
that 60% of the participants on the acupuncture arm
would achieve adequate relief for over a half of the study
period while up to 25% of those on the waitlist arm
would achieve such an outcome. Generally, a level of
significance of α = 0.05 and a power of 1–β = 0.80 were
used. The sample size in this trial was estimated accord-







pt 1−ptð Þ þ pc 1−pcð Þ
q 2
= pt− pcð Þ2
Assuming pt = 0.6 (pt: the effect of the acupuncture
group) and pc = 0.25 (pc: the effect of the waitlist group),
a sample size of n = 30.1 is calculated to achieve 5% of
significance level and 80% power. Considering an as-
sumed dropout rate of 20%, a total of 76 participants will
be needed with 1:1 allocation to each group (38 partici-
pants per group). First, both centers will respectively re-
cruit 30 patients each. After that, the remaining 16
patients will be recruited and randomized competitively
to include 76 patients in total.
Statistical analysis
A statistical analysis will be performed by an independ-
ent statistician who is blinded to group allocation using
SPSS 21.0 (IBM SPSS Statistics, New York, USA). Our
independent statistician will have an access to the final
dataset which will be kept locked so that investigators
will have limited access. All data will be presented as
means and standard deviations or number (%), and all
analyses will be based on an intention-to-treat principle.
For intention-to-treat analysis, the last observation car-
ried forward rule will be applied. The statistical signifi-
cance level will be set at 0.05 (two-sided), with the 95%
confidence intervals.
Description of baseline characteristics and homogeneity of
the two groups
For the description of baseline characteristics, the mean
with standard deviation or range with minimum and
maximum for continuous data and frequency with per-
centage for dichotomous data will be reported. For the
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the two groups, a two-sample t-test for continuous data
and a χ2 test for dichotomous data will be performed. If
there are baseline characteristics showing statistical signifi-
cance between groups, analysis of covariance (ANCOVA)
or logistic regression will be used for analysis and adjust-
ment of baseline characteristics.
Primary outcome
The primary outcome, PR at 4 weeks, will be compared
between groups using the χ2 test or logistic regression.
Secondary outcomes
Repeated measure two-factor analysis will be used to
analyze the difference and mean change among baseline,
4 and 8 weeks, difference and mean change between
groups, and interaction between groups and observed
time. For dichotomous outcomes, the χ2 test or logistic
regression will be used. For the comparison of adverse
events (AEs) between groups, the χ2 test or Fisher’s exact
test will be performed.
Data management
To promote data quality, the data will be collected by
well-trained assessor and the double entry of the data
will be implemented by clinical research coordinators.
Safety
We will perform the following tests on all participants at
screening: white blood cell count, hemoglobin, hematocrit,
platelet, aspartate aminotransferase/alanine aminotrans-
ferase, gamma-glutamyl transpeptidase, blood urea nitro-
gen, creatinine, and erythrocyte sedimentation rate. These
tests will help us to exclude participants who have serious
diseases and abnormal liver, heart, kidney, or other organ
function.
Participants will be asked about AEs at each clinic visit
and during the 4-week telephone interviews. AEs will be
defined as any unexpected and unfavorable signs, symp-
toms, or diseases temporally associated with acupuncture
treatment. If any AEs occur, the appropriate treatment will
be provided to the participant immediately. During the
entire study, AEs will be recorded in the dedicated docu-
ment including its severity and causality which will then
be reviewed by the independent monitor.
Any serious AEs that are life-threatening or result in
hospitalization, death, or significant or persistent disabil-
ity will be promptly reported to the clinical research as-
sociate within 24 h from the time of recognition.
Quality control
As we do not expect serious safety concerns, outstand-
ing benefit, or futility in this study, no official Data Mon-
itoring Committee will be established in each hospital.Instead, to retain the accuracy and quality of the clinical
trial, the clinical research associate will conduct regular
monitoring by checking investigator study files, in-
formed consent forms, case report forms, compliance
with treatments, serious AEs, and data records.
Ethical approval and registration
This trial will be carried out according to the standards
of the International Committee on Harmonization on
Good Clinical Practice and the revised version of the
Declaration of Helsinki. Institutional review boards at
Kyung Hee University Korean Medicine Hospital and
Kyung Hee University Hospital at Gangdong, have ap-
proved an initial version of this protocol (KOMCIRB
2013–05 for Kyung Hee University Korean Medicine
Hospital and KHNMC-OH-IRB 2013–006 for the Kyung
Hee University Hospital at Gangdong) on 28 June and
29 July 2013, respectively. This trial is registered in the
ClinicalTrials.gov (NCT01921504). In addition, all inves-
tigators were trained to maintain the personal informa-
tion of study participants and signed a pledge to protect
the confidentiality of participants.
Discussion
To our knowledge, acupuncture treatment for FD has
not been intensively investigated. This article describes
the protocol of a randomized trial with a waitlist control
group to evaluate the effectiveness of usual acupuncture
practice for FD patients in Korea. We expect that the re-
sults will be able to answer whether acupuncture treat-
ments help adequate symptom improvement and quality
of life, and whether ghrelin secretion is associated with
acupuncture treatment, compared with the no acupunc-
ture group.
A placebo control group is essential to determine the
efficacy of a new treatment. Given that there exist some
published sham-controlled trials of acupuncture for FD
[4,19], some may argue that a sham acupuncture control
should be adopted to investigate specific effect of acu-
puncture. However, it is yet to be clearly understood
what specific components of acupuncture treatment
work in the perceived therapeutic effect of acupuncture
[50]. Sham controls used in the previous studies in-
cluded superficial needling at non-acupuncture points
with [4] or without electrical stimulation [19]. In our
view, none of them are inert, and we could not find any
rationale for a better choice of sham control for our
study. Non-pharmacological intervention studies pose
particular challenges to identify inactive control groups
that generate expectancy comparable to the study inter-
vention [20]. Thus, participants in the non-pharmacological
intervention studies are often randomly allocated to waitlist
control condition as a comparison to the treatment modality
of interest. In this context, we decided to conduct a waitlist
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vestigate how acupuncture might work against a group
without acupuncture treatment. As natural fluctuations of
symptoms in the disease process and high placebo response
are unique challenges in FD trials, we can also obtain valu-
able information for further studies on how acupuncture
treatment will affect symptoms of FD during the treatment
and over a month of follow-up against a waitlist control.
Additionally, a minimum treatment duration of 4 weeks that
reflects the symptom periodicity is recommended for a
treatment trial for functional gastrointestinal disorders [20].
Therefore, this will be the first Korean randomized con-
trolled trial testing the adequate acupuncture intervention in
terms of duration and reflecting everyday practice.
One of the crucial limitations of this study is that the
doctors and participants cannot be blinded to the group
allocation. Blinding refers to keeping key persons, such
as participants, healthcare providers, outcome assessors,
and data analysts, unaware of the treatment adminis-
tered or of the true hypothesis of the trial [51,52]. Al-
though all outcome measures will be administered and
collected by the blinded nurse to minimize the risk of
detection bias, and a statistician blind to group assign-
ment will perform analysis of the data, the problem of
participant unblinding still remains. We will carefully
discuss residual sources of bias and their potential im-
pact on clinical outcomes when we analyze the study
findings and prepare for publication.
Some may argue that selection of ghrelin as a target
mechanism may provide limited evidence. We under-
stand that a variety of factors have been suggested to be
associated with pathophysiology of FD [24-26]. Among
many, ghrelin has been shown to play an important role
in gastric motility, food intake, and potential gastropro-
tection against acute gastric mucosal injury [25,26].
However, to our best knowledge, there is no report on
how ghrelin is related to acupuncture treatment for FD.
Changes in ghrelin level after acupuncture, therefore,
may not completely explain how acupuncture might
work for symptom improvement in patients with FD.
Nevertheless, ghrelin can be one of the many possible
factors underlying the mechanism of acupuncture for
FD and this study will help add evidence on this.
Trial status
This study is currently recruiting participants. No in-
terim analyses are planned and the primary results will
be published by 2015.
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